GenQual is a private corporation and has an active and experienced Advisory Board:

Dr. David M. Jackson, Ph.D., Business Development at PrimeraDx, Inc. He was previously Senior Director, Companion Diagnostic Partnerships at QIAGEN, Inc. (formerly DxS). Dr. Jackson has extensive experience in companion diagnostic partnerships, business development,, and regulatory and commercialization strategy. He was previously VP Business Development & Licensing at DxS Ltd., which commercialized the therascreen® KRAS mutation assay (EU CE-IVD mark) as a companion diagnostic for colorectal carcinoma therapies Vectibix® and Erbitux®. He received his Ph.D. in Medicine and Physiology from the Boston University School of Medicine.

Dr. Luman Wing, Ph.D., Director, Executive Consultant, Scientific Consulting at Beckloff Associates, a wholly-owned subsidiary of Cardinal Health. He has over 18 years experience in management of therapeutic development programs, toxicology, pharmacokinetic and bioanalytical study design. He has extensive experience interacting with FDA via Information Packages, Investigational New Drug (IND) Applications, and New Drug Applications (NDA). Dr. Wing received his Ph.D. in Biochemistry at the University of Aberdeen, Scotland, UK.

Scott Burell, Chief Financial Officer of Combimatrix. Prior to this, Mr. Burell had served as the Vice President of Finance since November 2001 and as the Controller from February 2001 to November 2001. From May 1999 to first joining CombiMatrix in February 2001, Mr. Burell was the Controller for Network Commerce, Inc., a publicly traded technology and information infrastructure company located in Seattle. Prior to this, Mr. Burell spent 9 years with Arthur Andersen’s Audit and Business Advisory practice in Seattle. Mr. Burell obtained his Washington state CPA license in 1992 and is a certified public accountant (currently inactive) and holds Bachelor of Science degrees in Accounting and Business Finance from Central Washington University. www.combimatrix.com

Howard Mendelsohn, Chief Financial and Operating Officer of Sustainable Fisheries Partnership. He brings over 20 years of industry experience in a variety of senior financial and operating roles. He has been a consulting advisor, providing financial models and lending his expertise to our development. Previously he served in senior management of Expedia, Inc. where he oversaw the company’s worldwide financial operations. He studied biochemistry and business at the University of California and University of Washington and is a Certified Management Accountant.

Dr. Philip Mease, MD, Clinical Professor at the University of Washington School of Medicine in Seattle, Director of the Rheumatology Clinical Research Division of Swedish Medical Center, and his clinical practice is based at Seattle Rheumatology Associates. He conducts clinical trials of emerging therapies for rheumatic diseases such as rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, fibromyalgia, osteoarthritis and lupus. He conducts research in disease state metrics and is the Co-Chair of three working groups of OMERACT (Outcome Measures in Rheumatology Clinical Trials) on psoriatic arthritis, fibromyalgia and single joint assessment, as well as being a member of the Soluble Biomarker working group. He is a founding organizer and President of GRAPPA (Group for Research and Assessment of Psoriasis and Psoriatic Arthritis), a member of SPARTAN (Spondyloarthritis Research & Treatment Network), and a member of TREG (The Rheumatology Education Group).

Dr. Mease received his undergraduate and medical degrees from Stanford University Medical School. He completed his residency in internal medicine at the University of Washington School of Medicine, where he also served as chief resident and fellow in rheumatology. He is the author of over 140 journal articles and 13 book chapters in texts including Biologics in General Medicine (Springer-Verlag, 2007), Update in Targeted Therapies in Rheumatology (Lippincott, 2007), and Rheumatology (in press). He has been the recipient of the Medical Communicator Award of the American College of Rheumatology.

Todd Young, Content Publishing Manager at Microsoft Corporation where he has served as a Documentation Manager, Content Publishing Lead, Technical Editor and Project Manager on products such as Microsoft Windows and Office since 1996. Mr. Young previously co-founded Saga Software, Inc. which developed a social shopping experience for mobile users.  He received his BA English and Writing from the University of Washington. www.microsoft.com